Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Biofluid Biopsies & High-Value Diagnostics 2015

Shana Kelley's Biography

Shana Kelley, Professor, University of Toronto

Dr. Shana Kelley is a Distinguished Professor of Chemistry, Biochemistry, Pharmaceutical Sciences, and Biomedical Engineering at the University of Toronto. Dr. Kelley received her Ph.D. from the California Institute of Technology and was a NIH postdoctoral fellow at the Scripps Research Institute. The Kelley research group works in a variety of areas spanning bioanalytical chemistry, chemical biology and nanotechnology. Shana’s group has developed novel electrochemical sensors that enable ultrasensitive nucleic acids detection for clinical diagnostics, and has also investigated a new set of chemical probes that interact with intracellular nucleic acids. The Kelley labs also use nucleic acids as building blocks for complex nanomaterials assembly. Dr. Kelley’s work has been recognized with a variety of distinctions, including being named one of “Canada’s Top 40 under 40”, a NSERC E.W.R. Steacie Fellow, and the 2011 Steacie Prize. She has also been recognized with the Pittsburgh Conference Achievement Award, an Alfred P. Sloan Research Fellowship, a Camille Dreyfus Teacher-Scholar award, a NSF CAREER Award, a Dreyfus New Faculty Award, and was also named a “Top 100 Innovator” by MIT’s Technology Review. She is a founder of two molecular diagnostics companies, GeneOhm Sciences (acquired by Becton Dickinson in 2005) and Xagenic Inc.

Shana Kelley Image

Profiling CTC Heterogeneity in Patients Using Microfluidics

Tuesday, 17 November 2015 at 10:00

Add to Calendar ▼

The analysis of circulating tumor cells (CTCs) is an important capability that may lead to new approaches for cancer management.  CTC capture devices developed to date isolate a bulk population of CTCs and do not differentiate subpopulations that may have varying phenotypes with different levels of clinical relevance.  Here, we present a new device for CTC spatial sorting and profiling that sequesters blood-borne tumor cells with different phenotypes into discrete spatial bins. Antibody-functionalized magnetic nanoparticles facilitate CTC sorting, and permit deconvolution of phenotypic subpopulations. Working with patient blood samples, we obtain profiles that elucidate the heterogeneity of CTC populations present in cancer patients.  Samples from patients undergoing treatment for prostate, breast, and renal cancers have been analyzed using this approach, and samples collected from xenograft cancer models have also been used for validation of the approach.

Add to Calendar ▼2015-11-16 00:00:002015-11-17 00:00:00Europe/LondonBiofluid Biopsies and High-Value Diagnostics 2015Biofluid Biopsies and High-Value Diagnostics 2015 in Boston, USABoston,